SEARCH:   Advanced

Blood, Vol. 114, Issue 10, 2168-2171, September 3, 2009 This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors Blood Soverini et al. 114: 2168 Supplemental materials for: Soverini et al Files in this Data Supplement: Figure S1. Results according to Bcr-Abl KD baseline mutation status in the subset of patients with CP CML who failed IM and switched to a second TKI (JPG, 62.5 KB) - Figure S2. Results according to Bcr-Abl KD baseline mutation status in the subset of patients with AP/BC CML who failed IM and switched to a second TKI (JPG, 63.9 KB) - Figure S3. Results according to Bcr-Abl KD baseline mutation status in the subset of patients with Ph+ ALL who failed IM and switched to a second TKI (JPG, 57.8 KB) - Figure S4. Results according to Bcr-Abl KD baseline mutation status in the subset of patients with CP CML who failed second TKI and switched to a third TKI (JPG, 61.3 KB) - Figure S5. Results according to Bcr-Abl KD baseline mutation status in the subset of patients with AP/BC CML who failed second TKI and switched to a third TKI (JPG, 62.3 KB) - Figure S6. Results according to Bcr-Abl KD baseline mutation status in the subset of patients with Ph+ ALL who failed second TKI and switched to a third TKI (JPG, 61 KB) - This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020